Results 1 to 10 of about 509,395 (261)
Process development for production of non-originator NISTmAb from CHO and NS0 cell lines
Cell lines that produce non-originator versions of the National Institute of Standards and Technology (NIST) monoclonal antibody reference material 8671 (NISTmAb) are invaluable to the biopharmaceutical industry because, unlike typical commercial cell ...
Erica J. Fratz-Berilla +4 more
doaj +1 more source
In February 2015, 23andMe received clearance from the United States Food and Drug Administration (FDA) for a carrier status test for a gene linked to Bloom syndrome.
Margaret Curnutte
doaj +1 more source
Currently, only Palivizumab and Nirsevimab that target the respiratory syncytical virus (RSV) fusion protein are licensed for pre-treatment of infants. Glycoprotein-targeting antibodies may also provide protection against RSV.
Youri Lee +5 more
doaj +1 more source
Exposure to a Titanium Dioxide Product Alters DNA Methylation in Human Cells
The safety of titanium dioxide (TiO2), widely used in foods and personal care products, has been of ongoing concern. Significant toxicity of TiO2 has been reported, suggesting a risk to human health.
Carlos Wells +7 more
doaj +1 more source
Maternal milk-derived lipids dictate neonatal macrophage phenotype and function
Summary: Unique properties of neonatal macrophages play an important role in tissue regeneration and susceptibility to infections. We discovered that exposure to neonatal mouse serum is sufficient to convert adult mouse macrophages into the neonatal ...
Lunhua Liu +6 more
doaj +1 more source
Regulatory Science Needs for Neonates: A Call for Neonatal Community Collaboration and Innovation
Susan K McCune, Yeruk Ager Mulugeta
doaj +1 more source
Benefit-risk assessment (BRA) plays a vital role in the development and approval of drugs and biologics, including vaccines. The U.S. Food and Drug Administration recently published the final guidance “Benefit-Risk Assessment for New Drugs and Biological
Hong Yang +5 more
doaj +1 more source

